Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. - sprookjes - yvandenbroek - TriplyDB

Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins.

Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins.

http://www.wikidata.org/entity/Q43114504

about

Subtype-specific therapy for autoimmune neuropathies?Novel immunotherapeutic strategies in chronic inflammatory demyelinating polyneuropathy.Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy.Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications.Severe refractory CIDP: a case series of 10 patients treated with bortezomib.Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab.Novel Therapeutic Avenues for Chronic Inflammatory Demyelinating Polyneuropathy: The Difficulties of Disease Diversity.Chronic Inflammatory Demyelinating Polyneuropathy Variant with Creatine-Kinase Elevation and Vanishing Effect of Immunoglobulins.Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy.Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15.Neurofascin antibodies in autoimmune, genetic, and idiopathic neuropathies.ARTHUR ASBURY LECTURE: Chronic inflammatory demyelinating polyradiculoneuropathy: clinical aspects and new animal models of auto-immunity to nodal components.Neurofascin-155 IGG4 Neuropathy: Pathophysiological Insights, Spectrum of Clinical Severity and Response To treatment.Unconventional treatments for chronic inflammatory demyelinating polyneuropathy.Auto-antibodies to contactin-associated protein 1 (Caspr) in two patients with painful inflammatory neuropathy.Comparing treatment options for chronic inflammatory neuropathies and choosing the right treatment plan.Rituximab in refractory chronic inflammatory demyelinating polyradiculoneuropathy: report of four cases.A New Classification System for IgG4 Autoantibodies.Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects.A new treatment regimen with high-dose and fractioned immunoglobulin in a special subgroup of severe and dependent CIDP patients.Head and voice tremor improving with immunotherapy in an anti-NF155 positive CIDP patient.Autoantibodies Against the Node of Ranvier in Seropositive Chronic Inflammatory Demyelinating Polyneuropathy: Diagnostic, Pathogenic, and Therapeutic Relevance.The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis.Diagnostic insights into chronic-inflammatory demyelinating polyneuropathies Detection Methods for Autoantibodies in Suspected Autoimmune Encephalitis

P2860

Q36092674-39CA63DF-0A1D-40DD-BDC4-7379C8629254 Q38711142-47319C47-5B9D-4752-8CFE-25E0688C78B5 Q38748481-2D8568F3-A958-48D1-A3A7-98308F3051E1 Q39434973-DCB4CA78-9553-4F42-9E77-E585B0F5BA3A Q40081746-651457CB-7A4E-432C-A1C7-2CD5699E415E Q40097140-B40B990A-82DF-4ACD-A28F-BDB4775A779F Q41002811-D3684FBC-658D-41D0-8990-A4923D50B9D0 Q41253790-715BDCEC-8DF4-4721-B8DA-FAD905D6C601 Q43533051-00D67FFC-108A-4604-B586-290B37FEB82F Q46866734-670C0FD7-0677-48B1-99F0-21891B4FDDD1 Q47327481-83D60A18-A4AE-4753-BBE1-307BE2F8129F Q47610103-E4F86384-A5DC-4150-AAEB-4BFFEC06F8DE Q47611455-57068059-5365-429A-9051-55D1445A8D27 Q48013653-00177130-EE53-4E7E-B48A-63BB0CABAC82 Q48033560-D9BFAEF5-3AA5-4ACC-8F78-6CC75ABD0972 Q48301410-1479D808-D8EC-4D83-97F7-951C38C01D8B Q48366711-E2D64FBA-7632-412B-9900-7C96685AB9C7 Q50327901-01F4CDB4-B33C-40AA-A8FC-DF5CC2BA1089 Q53174125-35F12243-142E-4B1C-86BD-8163AA32916F Q53647790-FF7B8EDC-A291-48F6-A8B2-66CD773251CF Q53821750-AD28CC3A-EF8C-4D12-AEEC-7CFC580C0BC9 Q55021064-8214E08C-00BD-42F4-B0CF-E021A28810AD Q55228908-B609B3F3-4F5D-467D-93A0-330AC8B9389A Q57300562-1A999C3D-B455-4035-AE7D-8A67C7E94DF6 Q58576008-223E6302-FC25-4421-B168-4FE817798623

P2860

Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins.

http://www.wikidata.org/entity/Q43114504

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins.

@en

Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins.

@nl

type

label

Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins.

@en

Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins.

@nl

prefLabel

Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins.

@en

Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins.

@nl

P1433

Q43114504-123E54C7-5765-4759-870A-48B87DEBB4FE

P1476

Q43114504-8750EF8D-2C1D-44D8-A92D-55AF6B4344A8

P2093

Q43114504-43E31675-2B9B-4D8C-9835-337315DD4A8F

Q43114504-542BB50D-BF9A-4FF8-A7E0-476DF1DA59D2

Q43114504-64B93B8C-F9B2-47CB-B008-A435520C43D1

Q43114504-A9C4C19F-75BF-4197-88F1-827F5E1C66FC

Q43114504-AF89C2D6-BE64-4D71-B1C4-685A717F8A42

Q43114504-CEEBCAA1-563E-4D09-8B2D-F7681222705F

Q43114504-F8EF36BE-7EBE-4107-A34A-EFD5131F231C

P2860

Q43114504-0396568C-5C08-4C29-B67E-46A4F68593D0

Q43114504-099B6460-D920-4DD5-A9E1-6EE49F6614AA

Q43114504-1CEDCC13-27F5-446B-9C7F-CDBCAD776B43

Q43114504-1E4E1F75-B1FB-415A-8A34-96460ADB44D6

Q43114504-48685763-55D2-4D40-A4B1-BFAC51A83B52

Q43114504-55350F45-BDE5-48D8-BE1E-8B402D479868

Q43114504-5603CACA-0D11-42AA-A698-4698BCABE45B

Q43114504-5D6640CE-24EF-4A8D-A3CE-9057A755EC8F

Q43114504-61F1FB71-59A0-4BC0-9959-F463B4534D80

Q43114504-62E945F6-8610-45DB-8A60-FC2926AE6388

P304

Q43114504-273E733B-ABE3-4896-8BA1-B8DD3F22F2DA

P31

Q43114504-31CEDE46-BC32-41A2-9589-A49550DB14C5

P356

Q43114504-82CD633B-BEBF-4B31-87CC-DDA69706E4E3

P433

Q43114504-F53EAF15-4899-4A25-98BE-DA45EF543D78

P478

Q43114504-38D32C73-3F91-429F-A327-85BE70EAC141

P50

Q43114504-5037CF50-E681-462D-9FB8-6E19201A5109

Q43114504-CCA031EB-F036-42D3-8750-BED755D46C64

Q43114504-DA56C364-8BC4-4337-A4E3-A6C6491C79B0

Q43114504-E0384948-A58A-4BA9-84E7-9E2C77AEA133

Q43114504-F65948EF-084D-4537-8E33-DCDE3DCBC322

P577

Q43114504-B7CE7C7B-AF85-416D-AE7D-AD022A9DDB21

P5875

Q43114504-23E9DBC2-0521-43C8-B7C2-9201F62540BD

P698

Q43114504-1F72A2F9-CAE7-4FE7-9A54-83BA9455DECB

P921

Q43114504-D5CB7EE9-0F74-4FBD-82C5-E5431D527DF3

P932

Q43114504-FE3836B6-F5E0-4FAD-ACF4-C39D1E3C6BEE

P356

NXI.0000000000000149

P1433

Neurology(R) neuroimmunology & neuroinflammation

P1476

Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins

@en

P2093

Alejandra Carvajal

http://www.w3.org/2001/XMLSchema#string

Angel Ortega-Moreno

http://www.w3.org/2001/XMLSchema#string

Isabel Illa

http://www.w3.org/2001/XMLSchema#string

Laia Seró-Ballesteros

http://www.w3.org/2001/XMLSchema#string

Luis Querol

http://www.w3.org/2001/XMLSchema#string

Maria Jose Sedano

http://www.w3.org/2001/XMLSchema#string

Nicolau Ortiz

http://www.w3.org/2001/XMLSchema#string

P2860

Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy

Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies

Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg.

Spatiotemporal ablation of myelinating glia-specific neurofascin (Nfasc NF155) in mice reveals gradual loss of paranodal axoglial junctions and concomitant disorganization of axonal domains.

A single cycle of rituximab for the treatment of severe pemphigus.

Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy.

Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype.

A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale.

Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia

Neurofascin as a target for autoantibodies in peripheral neuropathies.

P304

e149

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/NXI.0000000000000149

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Jordi Díaz-Manera

Eduard Gallardo

R Rojas-García

P577

2015-09-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

282153059

http://www.w3.org/2001/XMLSchema#string

P698

26401517

http://www.w3.org/2001/XMLSchema#string

P921

P932

4561230

http://www.w3.org/2001/XMLSchema#string